

**The YODA Project
Research Proposal Due Diligence Assessment**

Part 1: General Information	
YODA Project (Protocol) ID:	2020-4236
Date:	18 March 2020
Product Name:	Ibrutinib
Therapeutic Area:	Oncology
Product Class:	kinase inhibitors
Condition(s) Studied:	Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
Protocol Number(s) and Title(s):	NCT01722487/ PCYC-1115-CA -Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Part 2: Data Availability	
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments:	
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments:	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments:	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments:	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments:	
Part 3: Data Availability Summary	
Based on the responses to the above Data Availability questions, the requested clinical trial data are available for a data sharing request.	Yes
Part 4: Proposal Review	
Question:	Response:
Summary-level CSR data is appropriate for the proposed analysis.	No
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	Yes
Comments:	Janssen and PCYC are currently conducting a similar analysis to what is being proposed here and will include data from the same dataset (PCYC-1115) being requested here.